Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Rivoltini

Showing results (21-30 of 82) with videos related to

Pageof 9
Sort By:
Cancer Research|December 11, 1997
T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytesD J Cole, M C Wilson, L Rivoltini, et al.
Blood|August 9, 2001
Tumor necrosis factor-alpha induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surfaceK Hallermalm, K Seki, C Wei, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administrationA Caraceni, C Martini, F Belli, et al.
Scandinavian Journal of Immunology|November 1, 1993
The detection and biological activity of human antibodies to IL-2 in normal donorsL Tiberio, A Caruso, A Pozzi, et al.
Cell Death and Differentiation|October 13, 2007
Tumour-released exosomes and their implications in cancer immunityM Iero, R Valenti, V Huber, et al.
Cancer Research|February 24, 2001
Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cellsC Castelli, A M Ciupitu, F Rini, et al.
International Journal of Cancer|July 1, 1994
Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cellsS L Topalian, L Rivoltini, M Mancini, et al.
International Journal of Cancer|April 22, 1993
In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5L Rivoltini, V Viggiano, S Spinazzè, et al.
Cancer Immunology, Immunotherapy : CII|September 1, 1994
Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patientsA Boiardi, A Silvani, P A Ruffini, et al.
International Journal of Cancer|March 12, 1991
The high lysability by LAK cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less-differentiated phenotypeL Rivoltini, G Cattoretti, F Arienti, et al.
Pageof 9

Showing results (21-30 of 82) with videos related to

Sort By:
Pageof 9
Cancer Research|December 11, 1997
T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytesD J Cole, M C Wilson, L Rivoltini, et al.
Blood|August 9, 2001
Tumor necrosis factor-alpha induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surfaceK Hallermalm, K Seki, C Wei, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administrationA Caraceni, C Martini, F Belli, et al.
Scandinavian Journal of Immunology|November 1, 1993
The detection and biological activity of human antibodies to IL-2 in normal donorsL Tiberio, A Caruso, A Pozzi, et al.
Cell Death and Differentiation|October 13, 2007
Tumour-released exosomes and their implications in cancer immunityM Iero, R Valenti, V Huber, et al.
Cancer Research|February 24, 2001
Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cellsC Castelli, A M Ciupitu, F Rini, et al.
International Journal of Cancer|July 1, 1994
Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cellsS L Topalian, L Rivoltini, M Mancini, et al.
International Journal of Cancer|April 22, 1993
In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5L Rivoltini, V Viggiano, S Spinazzè, et al.
Cancer Immunology, Immunotherapy : CII|September 1, 1994
Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patientsA Boiardi, A Silvani, P A Ruffini, et al.
International Journal of Cancer|March 12, 1991
The high lysability by LAK cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less-differentiated phenotypeL Rivoltini, G Cattoretti, F Arienti, et al.
Pageof 9